Viewing

News

A dark adaptometer (AdaptDx; MacuLogix Inc) can aid in the diagnosis of early-stage, or subclinical, age-related macular degeneration before visual loss occurs and even before structural changes are observed, and adds to the information obtained from retina cameras and OCT imaging.

Early results of a phase Ib/II study investigating light-activated AU-011 (Aura Biosciences) for treatment of small-medium choroidal melanoma show good safety and evidence of efficacy for this novel tumor-targeted therapy.

Management of patients with loss of light perception after open-globe injury has historically been to observe or enucleate the eye with the goal of reducing the risk of sympathetic ophthalmia. Existing data, however, support rethinking that paradigm and instead considering surgery for carefully selected patients who have a chance for recovering vision.